Trial reportThe International journal of eating disorders2007
Placebo response in binge eating disorder.
Trial report in The International journal of eating disorders, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 43 citations in OpenAlex.
- Expectation shapes hunger and craving: placebo effects of verbal suggestion on food-related experiences.Annals of behavioral medicine : a publication of the Society of Behavioral Medicine · 2026Trial
- Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial.Obesity (Silver Spring, Md.) · 2023Trial
- Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects.Molecular psychiatry · 2013Trial
- Effects of mu opioid receptor antagonism on cognition in obese binge-eating individuals.Psychopharmacology · 2012Trial
- Combined Oral Contraceptive Use and Binge Eating.JAMA network open · 2026Article
- Effects of Open-Label Placebos on Visual Food Cue Reactivity in Children and Adolescents.Children (Basel, Switzerland) · 2024Article
- A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder.Obesity science & practice · 2023Article
- Taking Placebos as Needed to Reduce Appetite: A Randomized Controlled Trial with Ecological Momentary Assessment.Behavioral sciences (Basel, Switzerland) · 2023Article
- An exploratory machine learning approach to identify placebo responders in pharmacological binge eating disorder trials.Clinical and translational science · 2022Article
- Placebo Effects on Visual Food Cue Reactivity: An Eye-Tracking Investigation.Frontiers in psychiatry · 2019Article
- Combination Phentermine-Topiramate Extended Release for the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study.Innovations in clinical neuroscience · 2018Article
- Are loss of control while eating and overeating valid constructs? A critical review of the literature.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2017Review
- Albert J. Stunkard: His Research on Obesity and Its Psychological Impact.Current obesity reports · 2016Review
- Article
- Pharmacological management of binge eating disorder: current and emerging treatment options.Therapeutics and clinical risk management · 2012Article
- Clarifying boundaries of binge eating disorder and psychiatric comorbidity: a latent structure analysis.Behaviour research and therapy · 2011Article
- Diagnosis and management of binge eating disorder.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 9 institutions in 2 countries.
Funding
Abstract
objectivePlacebo response in studies of binge eating disorder (BED) has raised concern about its diagnostic stability. The aims of this study were (1) to compare placebo responders (PRs) with nonresponders (NRs); (2) to investigate the course of BED following placebo response; and (3) to examine attributions regarding placebo response.
methodThe baseline placebo run-in phase (BL) was part of a RCT investigating sibutramine hydrochloride for BED; it included 451 participants, ages 19-63, diagnosed with BED. Follow-up (FU) included 33 PRs.
results: In this study, 32.6% of participants responded to placebo (PRs = 147; NRs = 304). PRs exhibited significantly less symptom severity. At FU (n = 33), many PRs reported continued symptoms.
conclusionPRs exhibited significantly less severe pathology than NRs. Placebo response in BED may transitory or incomplete. The results of this study suggest variable stability in the BED diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.